GOLIMUMAB SAFETY ACCORDING TO CLINICAL FINDINGS
The review analyzes trials dealing with the safety of golimumab (GLM) used in rheumatology. This drug was the latest Contact: Galina Lukina;gvl3@yandex.ru Поступила 12.05.14tumor necrosis factor α (TNF-α) inhibitor introduced into clinical practice and therefore the estimation of its tolerability...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2015-04-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2076 |
| _version_ | 1797862723319496704 |
|---|---|
| author | G. V. Lukina Ya. A. Sigidin |
| author_facet | G. V. Lukina Ya. A. Sigidin |
| author_sort | G. V. Lukina |
| collection | DOAJ |
| description | The review analyzes trials dealing with the safety of golimumab (GLM) used in rheumatology. This drug was the latest Contact: Galina Lukina;gvl3@yandex.ru Поступила 12.05.14tumor necrosis factor α (TNF-α) inhibitor introduced into clinical practice and therefore the estimation of its tolerability is particularly relevant. The data obtained in large-scale clinical trials suggest that GLM has a good safety profile. The most common adverse events (AE) were infections, more often mild. The rate of infections was higher with the use of GLM 100 mg than with that of 50 mg. The overall cancer rate did not increase during a follow-up of less than 160 weeks. However, the rate of lymphomas in patients receiving GLM 100 mg proved to be higher than in those taking GLM 50 mg, in the general population, and in the placebo group in particular. AE were evenly distributed among patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Overall, the findings are in agreement with the data on the safety of previously used TNF-α inhibitors. No fundamentally new AE have been encountered. It is necessary to accumulate data on the use of GLM in real clinical practice, which will be able to more objectively define its place in the current therapy of rheumatic diseases. |
| first_indexed | 2024-04-09T22:25:09Z |
| format | Article |
| id | doaj.art-69b737f9d3c544c3bfdff4314d0c52c5 |
| institution | Directory Open Access Journal |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| last_indexed | 2024-04-09T22:25:09Z |
| publishDate | 2015-04-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj.art-69b737f9d3c544c3bfdff4314d0c52c52023-03-22T13:45:50ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922015-04-0153220020410.14412/1995-4484-2015-200-2041966GOLIMUMAB SAFETY ACCORDING TO CLINICAL FINDINGSG. V. Lukina0Ya. A. Sigidin1V.A. Nasonova Research Institute of Rheumatology, MoscowV.A. Nasonova Research Institute of Rheumatology, MoscowThe review analyzes trials dealing with the safety of golimumab (GLM) used in rheumatology. This drug was the latest Contact: Galina Lukina;gvl3@yandex.ru Поступила 12.05.14tumor necrosis factor α (TNF-α) inhibitor introduced into clinical practice and therefore the estimation of its tolerability is particularly relevant. The data obtained in large-scale clinical trials suggest that GLM has a good safety profile. The most common adverse events (AE) were infections, more often mild. The rate of infections was higher with the use of GLM 100 mg than with that of 50 mg. The overall cancer rate did not increase during a follow-up of less than 160 weeks. However, the rate of lymphomas in patients receiving GLM 100 mg proved to be higher than in those taking GLM 50 mg, in the general population, and in the placebo group in particular. AE were evenly distributed among patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Overall, the findings are in agreement with the data on the safety of previously used TNF-α inhibitors. No fundamentally new AE have been encountered. It is necessary to accumulate data on the use of GLM in real clinical practice, which will be able to more objectively define its place in the current therapy of rheumatic diseases.https://rsp.mediar-press.net/rsp/article/view/2076safetyadverse eventsrheumatic diseases |
| spellingShingle | G. V. Lukina Ya. A. Sigidin GOLIMUMAB SAFETY ACCORDING TO CLINICAL FINDINGS Научно-практическая ревматология safety adverse events rheumatic diseases |
| title | GOLIMUMAB SAFETY ACCORDING TO CLINICAL FINDINGS |
| title_full | GOLIMUMAB SAFETY ACCORDING TO CLINICAL FINDINGS |
| title_fullStr | GOLIMUMAB SAFETY ACCORDING TO CLINICAL FINDINGS |
| title_full_unstemmed | GOLIMUMAB SAFETY ACCORDING TO CLINICAL FINDINGS |
| title_short | GOLIMUMAB SAFETY ACCORDING TO CLINICAL FINDINGS |
| title_sort | golimumab safety according to clinical findings |
| topic | safety adverse events rheumatic diseases |
| url | https://rsp.mediar-press.net/rsp/article/view/2076 |
| work_keys_str_mv | AT gvlukina golimumabsafetyaccordingtoclinicalfindings AT yaasigidin golimumabsafetyaccordingtoclinicalfindings |